Share-Based Payments - SOP 2015 (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 23, 2017	Aug. 25, 2016	Sep. 23, 2015	Apr. 02, 2015
Stock-Based Compensation Expense
Share-based compensation expense	$ 5,732	$ 2,545	$ 1,351
SOP 2015
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 7.83	$ 7.61	$ 0.00
Granted (in dollars per share)	9.02	8.02	7.61
Exercised (in dollars per share)		7.21
Forfeited (in dollars per share)	8.60	7.64	7.21
Outstanding balance at end of year (in dollars per share)	8.35	7.83	7.61
Vested and exercisable balance at end of year (in dollars per share)	$ 7.68	$ 7.52	$ 7.21
Options
Outstanding at beginning of year (in shares)	1,794,360	1,092,300	0
Granted (in shares)	1,458,300	922,130	1,093,550
Exercised (in shares)		(23,360)
Forfeited (in shares)	(207,761)	(196,710)	(1,250)
Outstanding at end of year (in shares)	3,044,899	1,794,360	1,092,300
Vested and exercisable at end of year (in shares)	989,656	425,210	86,620
Aggregate intrinsic value
Aggregate intrinsic value, outstanding	$ 9
Aggregate intrinsic value, vested and exercisable	3
Additional disclosures
Total intrinsic value of options exercised	0	$ 181	$ 0
Stock-Based Compensation Expense
Share-based compensation expense	$ 5,610	$ 2,450	$ 1,274
SOP 2015 | $4.06 per share to $11.00 per share
Awards Outstanding By Exercise Price
Options outstanding (in shares)	3,044,899
Exercise price minimum range	$ 4.06
Exercise price maximum range	$ 11.00
Weighted average remaining contractual life	8 years 4 months 24 days
SOP 2015 | Options
Share-Based Payments
Vesting period	4 years
Exercise period	10 years
Stock-Based Compensation Expense
Weighted-average grant date fair value (in dollars per share)	$ 5.05	$ 4.76	$ 7.07
Fair Value Assumptions
Expected term of options (in years)	6 years 1 month 6 days	6 years	2 years
Term of European central government bonds used to estimate risk free interest rate			6 years
Term of U.S. treasury securities used to estimate risk free interest rate	7 years	5 years
Unrecognized compensation expense
Total unrecognized compensation related to non-vested options (in dollars)	$ 10,100
Period of recognition of total unrecognized compensation related to options	1 year 3 months 18 days
SOP 2015 | Options | Minimum
Fair Value Assumptions
Expected volatility (as a percent)	55.60%	59.80%	55.00%
Risk-free interest rate (as a percent)	1.89%	1.15%	(0.40%)
SOP 2015 | Options | Maximum
Fair Value Assumptions
Expected volatility (as a percent)	62.00%	67.20%	70.00%
Risk-free interest rate (as a percent)	2.10%	2.09%	(0.21%)
SOP 2015 | Options | First year
Share-Based Payments
Vesting period	1 year
Percentage that vests during the period	25.00%
SOP 2015 | Options | Second, third, and fourth years
Share-Based Payments
Percentage that vests during the period	75.00%
Monthly vesting percentage	2.083%
Nabriva Therapeutics plc ("Nabriva Ireland") | SOP 2015 | Redomiciliation Transaction | Ordinary Shares
Share-Based Payments
Number of shares to be awarded for each option when exercised				10
Nabriva Therapeutics AG ("Nabriva Austria") | SOP 2015 | Common Stock
Share-Based Payments
Maximum number of shares authorized					346,235	177,499	95,000
Nabriva Therapeutics AG ("Nabriva Austria") | SOP 2015 | Redomiciliation Transaction | Common Stock
Share-Based Payments
Number of shares to be awarded for each option when exercised				1